Combined endurance and resistance exercise training in heart failure with preserved ejection fraction: a randomized controlled trial

IF 58.7 1区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
Frank Edelmann, Rolf Wachter, André Duvinage, Stephan Mueller, Isabel Fegers-Wustrow, Silja Schwarz, Jeffrey W. Christle, Elisabeth Pieske-Kraigher, Melchior Seyfarth, Markus Knapp, Marcus Dörr, Kathleen Nolte, Hans-Dirk Düngen, Christoph Herrmann-Lingen, Katrin Esefeld, Andreas Hagendorff, Mark J. Haykowsky, Gerd Hasenfuss, Volker Holzendorf, Christiane Prettin, Meinhard Mende, Burkert Pieske, Martin Halle
{"title":"Combined endurance and resistance exercise training in heart failure with preserved ejection fraction: a randomized controlled trial","authors":"Frank Edelmann, Rolf Wachter, André Duvinage, Stephan Mueller, Isabel Fegers-Wustrow, Silja Schwarz, Jeffrey W. Christle, Elisabeth Pieske-Kraigher, Melchior Seyfarth, Markus Knapp, Marcus Dörr, Kathleen Nolte, Hans-Dirk Düngen, Christoph Herrmann-Lingen, Katrin Esefeld, Andreas Hagendorff, Mark J. Haykowsky, Gerd Hasenfuss, Volker Holzendorf, Christiane Prettin, Meinhard Mende, Burkert Pieske, Martin Halle","doi":"10.1038/s41591-024-03342-7","DOIUrl":null,"url":null,"abstract":"Endurance exercise training (ET) is an effective treatment in heart failure with preserved ejection fraction (HFpEF), but the efficacy of resistance training in this patient population has been only scarcely evaluated. In this multicenter, randomized trial, we evaluated the effects of combined endurance and resistance training over 12 months in patients with HFpEF. The primary endpoint was a modified Packer score, including all-cause mortality, hospitalizations classified as potentially related to heart failure or exercise and changes in peak oxygen consumption ( $${\\dot{\\rm{V}}}{\\rm{O}}_2$$ ), diastolic function (E/e′), New York Heart Association (NYHA) class and global self-assessment (GSA). In total, 322 patients (mean age, 70 years; 192 females (59.6%) and 130 males (40.4%)) were randomized (1:1) to ET or usual care (UC). At 12 months, the modified Packer score showed an improvement in 33 ET patients (20.5%) and in 13 UC patients (8.1%) and showed a worsening in 69 ET patients (42.9%) and in 71 UC patients (44.1%) (Kendall’s tau-b = −0.073, P = 0.17). Although the primary endpoint was not met, clinically relevant differences favoring the ET group as compared to the UC group were observed for the following secondary endpoints: changes in peak $${\\dot{\\rm{V}}}{\\rm{O}}_2$$ (mean difference, 1.3 ml kg−1 min−1 (95% confidence interval (CI): 0.4–2.1)) and NYHA class (odds ratio = 7.77 (95% CI: 3.73–16.21)). No significant between-group differences were observed for other secondary endpoints, including change in E/e′, change in GSA, time to cardiovascular hospitalization or all-cause mortality. In conclusion, 1 year of combined endurance and resistance ET did not result in a significantly better modified Packer score, but it did result in improvements in important clinical parameters, such as peak $${\\dot{\\rm{V}}}{\\rm{O}}_2$$ and NYHA class, as compared to UC. ISRCTN registration: ISRCTN86879094 . In a multicenter, randomized trial, patients with heart failure with preserved ejection fraction who underwent a regimen of combined endurance and resistance exercise training over the course of 1 year did not show a statistically significant improvement in the modified Packer score—the primary efficacy endpoint—as compared to patients who received usual care, but they did show improvements in secondary endpoints for maximal oxygen consumption and NYHA heart failure class.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"31 1","pages":"306-314"},"PeriodicalIF":58.7000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41591-024-03342-7.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41591-024-03342-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Endurance exercise training (ET) is an effective treatment in heart failure with preserved ejection fraction (HFpEF), but the efficacy of resistance training in this patient population has been only scarcely evaluated. In this multicenter, randomized trial, we evaluated the effects of combined endurance and resistance training over 12 months in patients with HFpEF. The primary endpoint was a modified Packer score, including all-cause mortality, hospitalizations classified as potentially related to heart failure or exercise and changes in peak oxygen consumption ( $${\dot{\rm{V}}}{\rm{O}}_2$$ ), diastolic function (E/e′), New York Heart Association (NYHA) class and global self-assessment (GSA). In total, 322 patients (mean age, 70 years; 192 females (59.6%) and 130 males (40.4%)) were randomized (1:1) to ET or usual care (UC). At 12 months, the modified Packer score showed an improvement in 33 ET patients (20.5%) and in 13 UC patients (8.1%) and showed a worsening in 69 ET patients (42.9%) and in 71 UC patients (44.1%) (Kendall’s tau-b = −0.073, P = 0.17). Although the primary endpoint was not met, clinically relevant differences favoring the ET group as compared to the UC group were observed for the following secondary endpoints: changes in peak $${\dot{\rm{V}}}{\rm{O}}_2$$ (mean difference, 1.3 ml kg−1 min−1 (95% confidence interval (CI): 0.4–2.1)) and NYHA class (odds ratio = 7.77 (95% CI: 3.73–16.21)). No significant between-group differences were observed for other secondary endpoints, including change in E/e′, change in GSA, time to cardiovascular hospitalization or all-cause mortality. In conclusion, 1 year of combined endurance and resistance ET did not result in a significantly better modified Packer score, but it did result in improvements in important clinical parameters, such as peak $${\dot{\rm{V}}}{\rm{O}}_2$$ and NYHA class, as compared to UC. ISRCTN registration: ISRCTN86879094 . In a multicenter, randomized trial, patients with heart failure with preserved ejection fraction who underwent a regimen of combined endurance and resistance exercise training over the course of 1 year did not show a statistically significant improvement in the modified Packer score—the primary efficacy endpoint—as compared to patients who received usual care, but they did show improvements in secondary endpoints for maximal oxygen consumption and NYHA heart failure class.

Abstract Image

Abstract Image

联合耐力和阻力运动训练对保留射血分数的心力衰竭:一项随机对照试验
耐力训练(ET)是一种有效的治疗心力衰竭保留射血分数(HFpEF)的方法,但阻力训练在这类患者群体中的疗效评价甚少。在这项多中心随机试验中,我们评估了耐力和阻力联合训练对HFpEF患者超过12个月的影响。主要终点是修改后的Packer评分,包括全因死亡率、与心力衰竭或运动潜在相关的住院情况以及峰值耗氧量的变化(\({\dot{\rm{V}}}{\rm{O}}_2\))、舒张功能(E/ E’)、纽约心脏协会(NYHA)分级和总体自我评估(GSA)。共322例患者(平均年龄70岁;192名女性(59.6%)%) and 130 males (40.4%)) were randomized (1:1) to ET or usual care (UC). At 12 months, the modified Packer score showed an improvement in 33 ET patients (20.5%) and in 13 UC patients (8.1%) and showed a worsening in 69 ET patients (42.9%) and in 71 UC patients (44.1%) (Kendall’s tau-b = −0.073, P = 0.17). Although the primary endpoint was not met, clinically relevant differences favoring the ET group as compared to the UC group were observed for the following secondary endpoints: changes in peak \({\dot{\rm{V}}}{\rm{O}}_2\) (mean difference, 1.3 ml kg−1 min−1 (95% confidence interval (CI): 0.4–2.1)) and NYHA class (odds ratio = 7.77 (95% CI: 3.73–16.21)). No significant between-group differences were observed for other secondary endpoints, including change in E/e′, change in GSA, time to cardiovascular hospitalization or all-cause mortality. In conclusion, 1 year of combined endurance and resistance ET did not result in a significantly better modified Packer score, but it did result in improvements in important clinical parameters, such as peak \({\dot{\rm{V}}}{\rm{O}}_2\) and NYHA class, as compared to UC. ISRCTN registration: ISRCTN86879094.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nature Medicine
Nature Medicine 医学-生化与分子生物学
CiteScore
100.90
自引率
0.70%
发文量
525
审稿时长
1 months
期刊介绍: Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信